Raymon Pharma Announces Positive Phase I Clinical Results for RA1115-B1 Ophthalmic Solution, China's First-in-Class Eye Drop for Wet AMD

Recently, Suzhou Raymon Pharmaceuticals Company, Ltd. (Raymon Pharma) announced,RA1115-B1, a self-developed eye drop for the treatment of neovascular (wet) age-related macular degeneration (wAMD)The Phase I clinical trial hosted by Professor Youxin Chen and Associate Professor Rui Chen at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, has been completed and achieved positive results.

The clinical research data showed that RA1115-B1 demonstrated superior safety, tolerability, and pharmacokinetic characteristics in healthy subjects.

Wet age-related macular degeneration is a vision killer for middle-aged and elderly people. According to WHO statistics, among the globally irreversible blinding eye diseases, wet age-related macular degeneration ranks second. In China, the prevalence rate in people over 50 has reached more than 15%, and it gradually increases with age.

Professor Chen Youxin

Director of Ophthalmology, Peking Union Medical College Hospital

Professor Chen Youxin, Director of the Department of Ophthalmology at Peking Union Medical College Hospital, stated:

The current treatment for wet age-related macular degeneration mainly involves intravitreal injections. The RA1115-B1 eye drops developed by the Raymon Pharma team are innovative in both mechanism of action and method of administration, with excellent results from the Phase I clinical study. It is hoped that this will bring light to patients with ophthalmic diseases.

Associate Professor Chen Rui

Clinical Pharmacology Research Center, Peking Union Medical College Hospital

Associate Professor Chen Rui, head of the Phase I Clinical Trial Ward at the Clinical Pharmacology Research Center of Peking Union Medical College Hospital, stated:

The clinical trial design of eye drops has its particularity. The Phase I study of RA1115-B1 conducted scientific exploration in special pharmacokinetics, local safety, and efficacy evaluation, achieving favorable results and accumulating experience. Looking forward to better performance in later clinical trials.

Dr. Zhang Fei

Founder of Raymon Pharma

Dr. Zhang Fei, founder of Raymon Pharma, stated:

RA1115-B1 is an important innovative drug developed by Raymon Pharma in the field of fundus diseases. The results of Phase I clinical trials have provided a solid foundation for further clinical development.

About RA1115-B1

RA1115-B1, as a VEGF inhibitor, can block the phosphorylation of VEGFr-2 and inhibit VEGF-induced adhesion, proliferation, and migration of endothelial cells, reducing pathological angiogenesis, thereby alleviating leakage and hemorrhage's impact on the retina, and thus achieving the effect of improving vision.

About Raymon Pharma

Raymon Pharma, founded in 2018, is a company focused on the research and development of innovative ophthalmic drugs. Its founders and management team have many years of top-tier multinational pharmaceutical R&D and management experience and have participated in the development of multiple ophthalmology clinical projects. Since its establishment, the company has adhered to independent innovation, creating a unique ophthalmic drug molecular screening platform to meet the significant clinical needs both in China and internationally.

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reproduce it, please leave a message or send a notification to the WeChat Official Account backend, and include the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. Medicine Cube assumes no responsibility for any loss incurred by any party due to the use of the content herein.